Abstract
Nanoparticles have shown great promise for improving the efficacy of nucleic acid drugs that lack permeability and bioavailability needed for reaching their intracellular site of action. The pharmacokinetics of the nucleic acid nanomedicines contributes greatly to their pharmacodynamic and toxicity characteristics. The pharmacokinetics of nanomedicines is determined by their physiochemical properties, such as particle size, shape, surface charge, and surface modifications. This review presented the pharmacokinetic and pharmacodynamic perspectives of nucleic acid nanomedicines. The cellular trafficking of the nucleic acid nanomedicines after cellular uptake is also discussed. In addition, the review puts forward potential strategies for circumventing biological barriers to delivering and releasing nucleic acid drugs into their intracellular site of action, and perspectives in this rapidly evolving field.
Keywords: Antisense oligonucleotide, gene therapy, intracellular trafficking, microRNA, nanomedicine, pharmacodynamic, pharmacokinetic, plasmid DNA, small interfering RNA.
Current Pharmaceutical Biotechnology
Title:Nanomedicine based on Nucleic Acids: Pharmacokinetic and Pharmacodynamic Perspectives
Volume: 15 Issue: 9
Author(s): Chenguang Zhou, Zhaogang Yang and Lesheng Teng
Affiliation:
Keywords: Antisense oligonucleotide, gene therapy, intracellular trafficking, microRNA, nanomedicine, pharmacodynamic, pharmacokinetic, plasmid DNA, small interfering RNA.
Abstract: Nanoparticles have shown great promise for improving the efficacy of nucleic acid drugs that lack permeability and bioavailability needed for reaching their intracellular site of action. The pharmacokinetics of the nucleic acid nanomedicines contributes greatly to their pharmacodynamic and toxicity characteristics. The pharmacokinetics of nanomedicines is determined by their physiochemical properties, such as particle size, shape, surface charge, and surface modifications. This review presented the pharmacokinetic and pharmacodynamic perspectives of nucleic acid nanomedicines. The cellular trafficking of the nucleic acid nanomedicines after cellular uptake is also discussed. In addition, the review puts forward potential strategies for circumventing biological barriers to delivering and releasing nucleic acid drugs into their intracellular site of action, and perspectives in this rapidly evolving field.
Export Options
About this article
Cite this article as:
Zhou Chenguang, Yang Zhaogang and Teng Lesheng, Nanomedicine based on Nucleic Acids: Pharmacokinetic and Pharmacodynamic Perspectives, Current Pharmaceutical Biotechnology 2014; 15 (9) . https://dx.doi.org/10.2174/1389201015666141020155620
DOI https://dx.doi.org/10.2174/1389201015666141020155620 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
High-Content Screening and Mechanism-Based Evaluation of Estrogenic Botanical Extracts
Combinatorial Chemistry & High Throughput Screening Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target
Current Medicinal Chemistry Antifolate Inhibitors of Thymidylate Synthase as Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Moving Beyond VEGF for Anti-angiogenesis Strategies in Gynecologic Cancer
Current Pharmaceutical Design The Role of Phenolic Compounds in the Fight against Cancer – A Review
Anti-Cancer Agents in Medicinal Chemistry ELISA-based Protein Arrays: Multiplexed Sandwich Immunoassays
Current Proteomics Mitochondrial Dysfunction and Targeted Drugs: A Focus on Diabetes
Current Pharmaceutical Design Dietary Polyphenols for Treatment of Alzheimer’s Disease– Future Research and Development
Current Pharmaceutical Biotechnology Adding to the Mix: Fibroblast Growth Factor and Platelet-Derived Growth Factor Receptor Pathways as Targets in Non – small Cell Lung Cancer
Current Cancer Drug Targets Antimicrobial Peptides Present in Mammalian Skin and Gut are Multifunctional Defence Molecules
Current Pharmaceutical Design Triggering PIK3CA Mutations in PI3K/Akt/mTOR Axis: Exploration of Newer Inhibitors and Rational Preventive Strategies
Current Pharmaceutical Design Perspectives in Breast and Ovarian Cancer Chemotherapy by Nanomedicine Approach: Nanoformulations in Clinical Research
Current Medicinal Chemistry Management of Early Stage Cervical Cancer
Reviews on Recent Clinical Trials Human Kallikreins: Common Structural Features, Sequence Analysis and Evolution
Current Genomics Manipulation of Glycolysis in Malignant Tumors: Fantasy or Therapy?
Current Medicinal Chemistry Lactoferrin Suppresses Decreased Locomotor Activities by Improving Dopamine and Serotonin Release in the Amygdala of Ovariectomized Rats
Current Molecular Pharmacology Pleiotropic Effects of Fenofibrate
Current Pharmaceutical Design Relaxin as a Cardiovascular Hormone: Physiology, Pathophysiology and Therapeutic Promises
Cardiovascular & Hematological Agents in Medicinal Chemistry Anti-TNF Treatment in Rheumatoid Arthritis
Current Pharmaceutical Design Dual Inhibitors of PI3K/mTOR or mTOR-Selective Inhibitors: Which Way Shall We Go?
Current Medicinal Chemistry